Medication Aides: Regulations, Safety, & Practice Jill Budden, PhD.
Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic...
-
Upload
clifford-booth -
Category
Documents
-
view
215 -
download
0
Transcript of Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic...
![Page 1: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/1.jpg)
Outcome Targets :Outcome Targets :What to measure?What to measure?
SAROJINI BUDDEN MD, FRCP CSAROJINI BUDDEN MD, FRCP CDirector Rett Syndrome ClinicDirector Rett Syndrome ClinicAssociate Professor PediatricsAssociate Professor Pediatrics
Oregon Health & Sciences UniversityOregon Health & Sciences UniversityMedical Director Pediatric Development Medical Director Pediatric Development
Program Legacy Emanuel Children’s Program Legacy Emanuel Children’s Hospital Hospital
Portland, OregonPortland, Oregon
![Page 2: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/2.jpg)
MECP-2 mutationsMECP-2 mutationsOccur in 80-85 % classic Rett syndrome Occur in 80-85 % classic Rett syndrome Occur in approximately 30-35 % atypical casesOccur in approximately 30-35 % atypical cases
Rett syndrome is a Rett syndrome is a CLINICAL DIAGNOSISCLINICAL DIAGNOSISRett syndrome is Rett syndrome is not synonymous with MECP-2 not synonymous with MECP-2 mutationsmutations
MECP-2 mutations being identified in a wide range MECP-2 mutations being identified in a wide range ofof
phenotypes from fatal encephalopathy to mild phenotypes from fatal encephalopathy to mild learning learning
disabilities and in normal carriers due to randomdisabilities and in normal carriers due to randominactivation of X chromosomeinactivation of X chromosome
![Page 3: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/3.jpg)
Genotype-Phenotype Genotype-Phenotype StudiesStudies
Use with Caution!!!Use with Caution!!!
Rett syndrome is Rett syndrome is not synonymous with not synonymous with MECP-2 MECP-2
MutationsMutations
Should mothers of siblings with Should mothers of siblings with positive studies who have similar positive studies who have similar mutations be included as having RS???mutations be included as having RS???
![Page 4: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/4.jpg)
Use of Severity ScaleUse of Severity Scale
What scales does one use if a child shows What scales does one use if a child shows classic stagnation of development and over classic stagnation of development and over many years acquires ambulation and or use of many years acquires ambulation and or use of expressive language?expressive language?
Our current severity scale does not account for Our current severity scale does not account for late improvement late improvement
![Page 5: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/5.jpg)
Outcome measuresOutcome measures2 cases with Mutations2 cases with Mutations
VideosVideos
Classic Rett with emerging ambulation at 12 Classic Rett with emerging ambulation at 12 years continues to walk verbal no languageyears continues to walk verbal no language
Early onset delayed walking at 5 years. OnsetEarly onset delayed walking at 5 years. Onset of seizures, followed with hand ringing at 8 of seizures, followed with hand ringing at 8
yrs yrs Onset of language at 15 years continues to useOnset of language at 15 years continues to use language . language .
![Page 6: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/6.jpg)
Documenting Regression of Documenting Regression of motor functionmotor function
Consider age and document identifiable Consider age and document identifiable factors affecting motor skills factors affecting motor skills
See list below See list below Use simple measures of gross and fine motor Use simple measures of gross and fine motor
function (listed) Such a study is easily function (listed) Such a study is easily designed and simple to collaborate with designed and simple to collaborate with
other centersother centers
![Page 7: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/7.jpg)
Factors influencing poor Factors influencing poor motor outcomemotor outcome
Extreme hypotoniaExtreme hypotonia Marked rigidityMarked rigidity Leg length discrepencyLeg length discrepency Dystonic patternsDystonic patterns Rapidly Progressive Scoliosis Rapidly Progressive Scoliosis Sympathetic Dystrophy/Foot Sympathetic Dystrophy/Foot
DeformitiesDeformities Osteoporosis with or without Osteoporosis with or without
fracturesfractures
![Page 8: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/8.jpg)
Gross Motor Functional Gross Motor Functional ClassificationClassification
Best used in 3-12 years of ageBest used in 3-12 years of age Level 1: Clumsy child; no assistive devicesLevel 1: Clumsy child; no assistive devices Level 2: walks independently but limited in Level 2: walks independently but limited in
outdoor activitiesoutdoor activities Level 3: walks with assistive mobility Level 3: walks with assistive mobility
devicesdevices Level 4: Self-mobility severely limited even Level 4: Self-mobility severely limited even
with assistive deviceswith assistive devices Level5; No self mobility even with assistive Level5; No self mobility even with assistive
devicesdevices Palisano R et al DMCN 1997; 39;214-223
![Page 9: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/9.jpg)
MACSMACSManual Ability Manual Ability
Classification SystemClassification System I Handles objects easily and successfullyI Handles objects easily and successfully II Handles most objects but with somewhat II Handles most objects but with somewhat
reduced reduced
quality and/or speed of achievementquality and/or speed of achievement III Handles objects with difficulty; needs help toIII Handles objects with difficulty; needs help to
prepare and modify activities prepare and modify activities IV Handles limited selection of easily managedIV Handles limited selection of easily managed
objects in adapted situationsobjects in adapted situations V Does not handle objects and has severely limited V Does not handle objects and has severely limited
abilityability
to perform even simple actionsto perform even simple actions www.macs.nu/
![Page 10: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/10.jpg)
Suggested simple studies Suggested simple studies designed to measure designed to measure
effectiveness of medical effectiveness of medical treatmentstreatments
Suggest that the clinical Suggest that the clinical trials group look at these trials group look at these
and prioritizeand prioritize
![Page 11: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/11.jpg)
What should we What should we measure??measure??
Sleep:Sleep: Salivary Melatonin, actigraphic Salivary Melatonin, actigraphic studies studies
Agitation:Agitation: Sensory integration therapy (OT) Sensory integration therapy (OT) Medications: Naltrexone, Tranzene, Medications: Naltrexone, Tranzene,
Respiradol, Tegretol.Respiradol, Tegretol. Hyperactivity: Hyperactivity: Straterra, Concerta.Straterra, Concerta. Respiratory dysfunctionRespiratory dysfunction. Use of . Use of
Disipramine??Disipramine?? Seizures:Seizures: Early use and effectiveness of VNS Early use and effectiveness of VNS Depression: Depression: Prozac, Zoloft, Depakote.Prozac, Zoloft, Depakote.
![Page 12: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/12.jpg)
What should we What should we Measure?Measure?
Drooling:Drooling: Effectiveness of non invasive Effectiveness of non invasive methodsmethods
Swabbing mouth with food extract, Swabbing mouth with food extract,
Use of 1% Atropine Ophthalmic drops PO Use of 1% Atropine Ophthalmic drops PO Nutrition/growthNutrition/growth Keeping BMI normal and Keeping BMI normal and
maintaining optimal caloric and nutritional maintaining optimal caloric and nutritional intakeintake
Reflux-Esophageal dysmotility Reflux-Esophageal dysmotility Identification (Manometric studies) and Identification (Manometric studies) and treatment (medical and surgical ) treatment (medical and surgical )
Constipation: Constipation: Common and a chronic issueCommon and a chronic issue
![Page 13: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/13.jpg)
What should we What should we measure?measure?
Rigidity:Rigidity: Use of local BOTOX, Oral Baclofen, Use of local BOTOX, Oral Baclofen, L-Dopa L-Dopa Dystonia:Dystonia: Use of night time Valium, oral Use of night time Valium, oral
Baclofen, ArtaneBaclofen, Artane Reflex Sympathetic Dystrophy:Reflex Sympathetic Dystrophy: Use of Use of
Neurontin (Gabapentine)Neurontin (Gabapentine) Osteoporosis: Osteoporosis: Maintaining muscle strength, Maintaining muscle strength,
adequate Vit D, Calcium, and Vitamin C adequate Vit D, Calcium, and Vitamin C intakeintake
Fractures:Fractures: Treatment of fractures with Treatment of fractures with Pamidronate or Alaendronate (Fosamax)Pamidronate or Alaendronate (Fosamax)
![Page 14: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/14.jpg)
OsteoporosisOsteoporosis
Risk of fractures is quite highRisk of fractures is quite high Osteopenia is identified in young Osteopenia is identified in young
children who do not have any of the children who do not have any of the precipitating factorsprecipitating factors
Urine studies and blood work has not Urine studies and blood work has not been diagnostically usefulbeen diagnostically useful
Bone studies have shown that rate of Bone studies have shown that rate of bone formation is very low compared bone formation is very low compared to normsto norms
![Page 15: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/15.jpg)
Growth measurementsGrowth measurements
MicrocephalyMicrocephaly Short Stature/wt (BMI)Short Stature/wt (BMI) Small organs appropriate for heightSmall organs appropriate for height Poor muscle mass ( Impedence Poor muscle mass ( Impedence
studies)studies) Discrepency in skeletal growth Discrepency in skeletal growth Osteporosis as a result of poor bone Osteporosis as a result of poor bone
formationformation
![Page 16: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/16.jpg)
AgitationAgitation
In younger girls panic –like attacksIn younger girls panic –like attacks In older girls intermittent or In older girls intermittent or
constant screaming or moaningconstant screaming or moaning This needs identification and This needs identification and
treatmenttreatment At times there is a known cause but At times there is a known cause but
needs treatment needs treatment
![Page 17: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/17.jpg)
Causes of Agitation and Causes of Agitation and DistressDistress
RefluxReflux ConstipationConstipation InfectionsInfections Dental problemsDental problems Gall StonesGall Stones Surgical abdomen (often acute onset)Surgical abdomen (often acute onset) Dystonic spasmsDystonic spasms FracturesFractures
![Page 18: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/18.jpg)
Causes of Agitation and Causes of Agitation and DistressDistress(cont)(cont)
Reflexive Sympathetic DystrophyReflexive Sympathetic Dystrophy SeizuresSeizures HeadacheHeadache Long standing sleep deprivationLong standing sleep deprivation Premenstrual distressPremenstrual distress Urinary retentionUrinary retention Change in school Change in school Change in care giversChange in care givers AbuseAbuse
![Page 19: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/19.jpg)
Documentation of Documentation of DepressionDepression
This is being recognized more This is being recognized more frequently in those young frequently in those young women who are isolated from women who are isolated from family and friends and their family and friends and their earlier school based activities.earlier school based activities.
There is clearly an organic and There is clearly an organic and environmental basis to this.environmental basis to this.
![Page 20: Outcome Targets : What to measure? SAROJINI BUDDEN MD, FRCP C Director Rett Syndrome Clinic Associate Professor Pediatrics Oregon Health & Sciences University.](https://reader037.fdocuments.in/reader037/viewer/2022103023/56649e0e5503460f94af8f0d/html5/thumbnails/20.jpg)
Lessons learned and to Lessons learned and to be learntbe learnt
Early medical and therapeutic intervention Early medical and therapeutic intervention is useful and should be providedis useful and should be provided
The potential for functional development is The potential for functional development is unknown in young children with Rett unknown in young children with Rett SyndromeSyndrome
There is no one parameter that can be There is no one parameter that can be measuredmeasured
as best criteria of outcomeas best criteria of outcome Functional development needs to be Functional development needs to be
measured at different agesmeasured at different ages Outcomes based on genotype /phenotype Outcomes based on genotype /phenotype
need to be used with discretion need to be used with discretion